Scholarlink

Background <p>Early recognition of pediatric deterioration is difficult because age-dependent physiology and compensation mask early shock and safety risks. This narrative review compares vital-sign (VS) biomarkers (heart rate, respiratory rate, blood pressure, oxygen saturation, temperature) with laboratory markers and clinical indicators.</p> Methods <p>We searched Embase, Pubmed, and guideline repositories to August 2025 for pediatric studies from emergency, inpatient, and critical-care settings. We summarized accuracy, timeliness, and implementation issues, prioritizing cohort and implementation evaluations.</p> Results <p>Age-adjusted, repeated, and continuous analyses of VS—especially multivariate approaches such as shock index pediatric age-adjusted and heart-rate-characteristics analytics—outperformed single thresholds, often anticipating ICU transfer or sepsis by hours. Laboratory biomarkers provided diagnostic specificity for defined syndromes but were slower and unsuitable for continuous surveillance. Composite scores (e.g., PEWS, ED-PEWS, National PEWS) showed moderate to high discrimination yet performed best when integrated with trends and standardized escalation pathways.</p> Conclusion <p>VS biomarkers, leveraged as dynamic trends and combined with context, enable earlier, safer detection of pediatric deterioration than static thresholds or isolated laboratory tests. Priorities include validating continuous models beyond NICUs, ensuring equity and calibration across different ages and comorbidities, and testing wearable sensors and EHR-embedded alerts in pragmatic trials that measure timeliness, unintended harms, and patient-centered outcomes.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vital signs as biomarkers of early clinical deterioration in pediatric emergency departments: physiology, interpretation, and innovations: a narrative review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Mohamed Alsabri,
  • Marina Ramzy Mourid,
  • Amr R. Saleh,
  • Temitomi Jane Oyedele,
  • Israa Magdy Ata,
  • Sara M. Darawish,
  • Aanal Patel,
  • Faher AL Rouh,
  • Lauren A. Carr

摘要

Background

Early recognition of pediatric deterioration is difficult because age-dependent physiology and compensation mask early shock and safety risks. This narrative review compares vital-sign (VS) biomarkers (heart rate, respiratory rate, blood pressure, oxygen saturation, temperature) with laboratory markers and clinical indicators.

Methods

We searched Embase, Pubmed, and guideline repositories to August 2025 for pediatric studies from emergency, inpatient, and critical-care settings. We summarized accuracy, timeliness, and implementation issues, prioritizing cohort and implementation evaluations.

Results

Age-adjusted, repeated, and continuous analyses of VS—especially multivariate approaches such as shock index pediatric age-adjusted and heart-rate-characteristics analytics—outperformed single thresholds, often anticipating ICU transfer or sepsis by hours. Laboratory biomarkers provided diagnostic specificity for defined syndromes but were slower and unsuitable for continuous surveillance. Composite scores (e.g., PEWS, ED-PEWS, National PEWS) showed moderate to high discrimination yet performed best when integrated with trends and standardized escalation pathways.

Conclusion

VS biomarkers, leveraged as dynamic trends and combined with context, enable earlier, safer detection of pediatric deterioration than static thresholds or isolated laboratory tests. Priorities include validating continuous models beyond NICUs, ensuring equity and calibration across different ages and comorbidities, and testing wearable sensors and EHR-embedded alerts in pragmatic trials that measure timeliness, unintended harms, and patient-centered outcomes.

Clinical trial number

Not applicable.